STOCKWATCH

Windlas Biotech Ltd Reports Highest Ever Revenue and EPS in FY2025

Windlas Biotech Ltd, a leading Generic Formulations Contract Development and Manufacturing Organization (CDMO), has reported its highest ever revenue and EPS in FY2025. The company's revenue stands at 2,027 Million, with a strong liquidity and working capital days. The company operates five WHO-GMP certified manufacturing facilities and a DSIR-approved R&D centre. Windlas Biotech Limited is recognized for its deep technical capabilities, in-house intellectual property, and agile manufacturing infrastructure.

• Windlas Biotech reports highest ever revenue of 2,027 Million in FY2025
• Strong liquidity and working capital days
• Five WHO-GMP certified manufacturing facilities and a DSIR-approved R&D centre
• Recognized for deep technical capabilities and agile manufacturing infrastructure
• Continued growth in EPS post EBITDA